Alpha2delta-1-containing N-methyl-D-aspartate receptor complex (α2δ-1-NMDAR complex) (α2δ-1-NMDAR complex)

The alpha2delta-1-containing NMDA receptor complex is a heteromeric protein assembly consisting of the voltage-gated calcium channel auxiliary subunit alpha2delta-1 (encoded by CACNA2D1) and the N-methyl-D-aspartate receptor (NMDAR) [1, 9]. Traditionally recognized for its role in calcium channel trafficking, alpha2delta-1 has been recently identified as a direct interactor with NMDARs, particularly through its C-terminal domain [3, 5]. This interaction is pathologically upregulated following nerve injury, stroke, or chronic opioid exposure, where it promotes the surface trafficking and synaptic delivery of NMDARs [6, 11, 13]. The resulting NMDAR hyperactivity leads to synaptic plasticity changes, excitotoxicity, and the development of chronic neuropathic pain [7, 8]. Gabapentinoids, such as gabapentin and pregabalin, exert their therapeutic effects by binding to the alpha2delta-1 subunit and disrupting the forward trafficking of this complex to the plasma membrane [3, 9]. By specifically targeting the alpha2delta-1-bound fraction of NMDARs, these drugs can normalize pathological glutamatergic signaling without interfering with the physiological functions of alpha2delta-1-free NMDARs [1, 8]. This complex represents a novel mechanism for understanding the analgesic and neuroprotective properties of gabapentinoids beyond their traditional association with calcium channels [2, 6]. Research suggests that interrupting the physical coupling between these proteins could provide a more targeted approach for treating neurological disorders involving glutamate excitotoxicity [1, 11].

Other names

α2δ-1-NMDAR complexCACNA2D1-NMDAR complexAlpha2delta-1-bound NMDA receptorα2δ-1-containing NMDA receptorAlpha2delta-1-NMDA receptor complex

Gabapentinoids bind to the alpha2delta-1 subunit and inhibit the forward trafficking and surface expression of the alpha2delta-1-NMDAR complex, thereby normalizing NMDAR hyperactivity.